Physician profile
Mischell E Schlosser
NPI 1972070423
$1,980.34
in general payments reported to CMS, 2019-2025
20 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.74 · 2022: $14.00 · 2023: $414 · 2024: $882 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,895 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,895.34 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $238.25 | 2023-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $237.27 | 2022-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $236.92 | 2023-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $227.09 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $173.74 | 2023-2025 | Camzyos, Eliquis |
| Amgen INC. | $149.02 | 2023-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $127.19 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.00 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $98.08 | 2024-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $90.08 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $73.23 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Kiniksa Pharmaceuticals International, Plc | $38.49 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $33.67 | 2024 | |
| Janssen Pharmaceuticals, INC | $29.83 | 2021-2024 | Xarelto |
| Atricure, INC. | $27.32 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $25.80 | 2024 | |
| Pfizer INC. | $18.31 | 2025 | |
| Amarin Pharma, INC. | $15.67 | 2021 | |
| Philips North America LLC | $15.60 | 2024 | (Ck4) Mcot |
| Merck Sharp & Dohme LLC | $13.78 | 2025 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mischell Schlosser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.